Old drug fluvoxamine, new hope for COVID-19.

Through sigma-1 receptor chaperone activity [[1]], the sigma-1-receptor agonist fluvoxamine may attenuate ER stress due to SARS-CoV-2 replication in cells, thus resulting in a blockade against inflammatory events (i.e., cytokine storm). The coronavirus disease 2019 (COVID-19) is an acute respiratory disease caused by the novel coronavirus SARS-CoV-2. Taken together, it is likely that the potent sigma-1 receptor agonists, such as fluvoxamine, might ameliorate inflammatory events (i.e., cytokine storm) associated with ER stress due to SARS-CoV-2 replication (Fig. [Extracted from the article]